Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc. (OTLK), bought 10,000 shares at $1.82 ($18K) on 2021-04-19, disclosed to the SEC on 2021-04-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| OTLK | BUY | 2024-03-29 | $22K | — | Filing → |
| OTLK | BUY | 2022-10-11 | $43K | — | Filing → |
| OTLK | BUY | 2021-12-02 | $14K | — | Filing → |